Xeljanz

Xeljanz is a brand name for tofacitinib, a medication used to treat certain autoimmune conditions. It belongs to a class of drugs called Janus kinase (JAK) inhibitors. JAK inhibitors work by blocking the activity of Janus kinases, which are enzymes involved in the signaling pathways of immune cells that cause inflammation. By reducing this inflammation, Xeljanz can help alleviate symptoms associated with certain chronic inflammatory diseases.

Xeljanz is primarily prescribed for adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis. It is also used for polyarticular course juvenile idiopathic arthritis in patients 2 years of age and older. The medication is typically taken orally in tablet or extended-release tablet form. Its effectiveness is measured by a reduction in joint pain, swelling, and stiffness, as well as improvement in physical function and disease activity.

Like all medications, Xeljanz can cause side effects. Common side effects may include upper respiratory tract infections, headache, diarrhea, and an increase in cholesterol levels. More serious side effects can occur, including an increased risk of serious infections, blood clots, heart attack, stroke, and certain types of cancer. Patients taking Xeljanz are closely monitored by their healthcare provider for potential adverse effects. It is important for individuals to discuss their medical history and any concerns with their doctor before starting Xeljanz.